Viewray Inc (VRAYQ)

[realfast95]

Viewray (VRAY) Stock Rating Reaffirmed by Cantor Fitzgerald

Posted by ABMN Staff on Oct 3rd, 2018 // No Comments

Viewray logoViewray (NASDAQ:VRAY)‘s stock had its “buy” rating restated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They currently have a $13.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 36.84% from the company’s current price.

The analysts wrote, “We reiterate our Overweight rating on shares of VRAY and our 12-month price target of $13. VRAY has succeeded in bringing an MRI linear accelerator (linac) to the market when its larger competitors could not. VRAY’s differentiated technology has the potential to change radiation therapy longer term, but VRAY’s commercial launch is only in its infancy. Positive early clinical data are driving physician interest, but the price of the system comes at a significant premium (~50%) to existing linacs. VRAY, like many small capital equipment companies, comes with a good amount of risk, but we think the momentum is building.””

https://www.americanbankingnews.com/2018/10/03/viewray-vray-stock-rating-reaffirmed-by-cantor-fitzgerald.html